The risk of infections with tumor necrosis factor-α inhibitors

Research output: Contribution to journalArticle

Abstract

Serious infections have an increased incidence of occurrence in those prescribed TNF- inhibitors. although the incidence rate of infections may be broadly interpreted as minimal, when compared with those prescribed high-dose glucocorticoids, a thorough work-up must be considered in the context of TNF blockade (Table 3). If infections are suspected, then treatment must be immediately initiated along with careful consideration for the continuation of TNF-inhibitor therapy. Prevention must always be the basis of any initial evaluation and all appropriate immunization strategies should be implemented.

Original languageEnglish (US)
Pages (from-to)419-426
Number of pages8
JournalJournal of Clinical Rheumatology
Volume15
Issue number8
DOIs
StatePublished - Dec 2009

Fingerprint

Tumor Necrosis Factor-alpha
Infection
Incidence
Glucocorticoids
Immunization
Therapeutics

ASJC Scopus subject areas

  • Rheumatology

Cite this

The risk of infections with tumor necrosis factor-α inhibitors. / Jassal, Mandeep S; Bishai, William Ramses.

In: Journal of Clinical Rheumatology, Vol. 15, No. 8, 12.2009, p. 419-426.

Research output: Contribution to journalArticle

@article{21396e5a3e944edeb2061c6069defab9,
title = "The risk of infections with tumor necrosis factor-α inhibitors",
abstract = "Serious infections have an increased incidence of occurrence in those prescribed TNF- inhibitors. although the incidence rate of infections may be broadly interpreted as minimal, when compared with those prescribed high-dose glucocorticoids, a thorough work-up must be considered in the context of TNF blockade (Table 3). If infections are suspected, then treatment must be immediately initiated along with careful consideration for the continuation of TNF-inhibitor therapy. Prevention must always be the basis of any initial evaluation and all appropriate immunization strategies should be implemented.",
author = "Jassal, {Mandeep S} and Bishai, {William Ramses}",
year = "2009",
month = "12",
doi = "10.1097/RHU.0b013e3181c0696e",
language = "English (US)",
volume = "15",
pages = "419--426",
journal = "Journal of Clinical Rheumatology",
issn = "1076-1608",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - The risk of infections with tumor necrosis factor-α inhibitors

AU - Jassal, Mandeep S

AU - Bishai, William Ramses

PY - 2009/12

Y1 - 2009/12

N2 - Serious infections have an increased incidence of occurrence in those prescribed TNF- inhibitors. although the incidence rate of infections may be broadly interpreted as minimal, when compared with those prescribed high-dose glucocorticoids, a thorough work-up must be considered in the context of TNF blockade (Table 3). If infections are suspected, then treatment must be immediately initiated along with careful consideration for the continuation of TNF-inhibitor therapy. Prevention must always be the basis of any initial evaluation and all appropriate immunization strategies should be implemented.

AB - Serious infections have an increased incidence of occurrence in those prescribed TNF- inhibitors. although the incidence rate of infections may be broadly interpreted as minimal, when compared with those prescribed high-dose glucocorticoids, a thorough work-up must be considered in the context of TNF blockade (Table 3). If infections are suspected, then treatment must be immediately initiated along with careful consideration for the continuation of TNF-inhibitor therapy. Prevention must always be the basis of any initial evaluation and all appropriate immunization strategies should be implemented.

UR - http://www.scopus.com/inward/record.url?scp=74549160566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549160566&partnerID=8YFLogxK

U2 - 10.1097/RHU.0b013e3181c0696e

DO - 10.1097/RHU.0b013e3181c0696e

M3 - Article

C2 - 19956005

AN - SCOPUS:74549160566

VL - 15

SP - 419

EP - 426

JO - Journal of Clinical Rheumatology

JF - Journal of Clinical Rheumatology

SN - 1076-1608

IS - 8

ER -